"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"

Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction

The purpose of this study is to determine a preventative dose of study drug, Arixtra® for patients with kidney disease. We will measure the blood levels of Arixtra® in patients with kidney disease and develop guidelines for dosing.

Inclusion Criteria:

• Inpatients who are 18 years or older
• estimated creatinine clearances between 20-50 ml/min
• current hospitalization for a cancer-related abdominal, breast surgery or elective orthopedic surgery
• able to give informed consent
• need for prophylactic anticoagulant therapy for increased risk of a thrombotic episode

Exclusion Criteria: Use of the following

• clopidogrel, aspirin, or NSAID usage,(usage is prohibited while patients are participating in the study)
• body weight < 50 kg
• anticoagulation therapy for thrombosis or other indication
• pregnant or breast-feeding
• hypersensitivity to Arixtra®
• thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the presence of Arixtra®
• bacterial endocarditis
• brain malignancy
• increased risk of bleeding.